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1. Introduction 
The impact of nutritional status in acute pancreatitis (AP) has not been fully elucidated, but 
it is probable that severe malnutrition will adversely affect outcomes, as occurs in other 
critical diseases. Malnutrition is known to occur in 50-80% of chronic alcoholics and alcohol 
is a major etiological factor in AP. Morbid obesity is also associated with poorer prognosis 
(Gianotti L et al, 2009). Assessment of the severity of AP, together with the patient´s 
nutritional status is crucial in the decision-making process that determines the need or 
otherwise for nutrition support. Both should be done on admission and at frequent intervals 
thereafter.  
Substrate metabolism in AP is similar to that in response to severe sepsis or trauma. There is 
an increase in protein catabolism, characterized by an inability of exogenous glucose to 
inhibit gluconeogenesis, increased energy expenditure, increased insulin resistance and 
increase dependence of fatty acid oxidation to provide energy substrates. Energy needs may 
differ and change substantially according to the severity and stage of AP, comorbidities, and 
specific complications occurring during the clinical course of AP. 
Assessment criteria that can serve as early predictors of AP severity are often complex and 
not sufficiently accurate. However, several recently described criteria that rely on criteria 
such as the body mass index, physical findings, and simple laboratory measurements could 
prove useful if validated in large prospective studies (Talukdar R  et al,  2009). 
The factors that influence mortality in different degrees of severity of AP are various. 
Etiology, age, sex, race, ethnicity, genetic makeup, severity on admission, and the extent and 
nature of pancreatic necrosis (sterile vs. infected) influence the mortality. Other factors 
include treatment modalities such as administration of prophylactic antibiotics, parenteral 
nutrition (PN) vs. enteral (EN), endoscopic retrograde cholangio pancreatography with 
sphincterotomy, and surgery in selected cases. Epidemiological studies indicate that the 
incidence of AP is increasing along with an increase in obesity, a bad prognostic factor. Since 
Ranson reported early prognostic criteria, a number of attempts have been made to simplify 
or add new clinical or laboratory studies in the early assessment of severity. Obesity, 
hemoconcentration on admission, presence of pleural effusion, increased fasting blood 
sugar, as well as creatinine, elevated C-Reactive Protein in serum, and urinary trypsinogen 
levels are some of the well-documented factors (Pitchumoni CS et al, 2005). 
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We found evidence that some indicators of nutritional status could be of help in trying to 
predict mortality in AP, since nutritional status may be associated with final prognosis. 
Specifically in the case of severe AP, excess body fat, lack of lean body mass, muscle wasting 
and poor immune status seems to be related with poor prognosis (Fuchs-Tarlovsky V et al, 
2010; Fuchs-Tarlovsky V et al, 1997). 
PN in the past has always appeared ideally suited as the preferred route for nutrition 
support over EN in patients with AP. The pathophysiology of the disease process involves a 
catabolic stress state, elevated caloric requirements; reduction in pancreatic stimulation or 
“pancreatic rest” appeared to be needed to allow resolution of inflammation within the 
gland. However, evidence has emerged that other pathophysiologic processes outside the 
pancreas itself may contribute to the stress state seen in these patients. Failure to use the gut 
may actually exacerbate the stress response, prolong the duration and severity of the 
disease, and increase the likelihood of complications (McClave SA et al, 2006; Lugli AK et al, 
2007). 
More recent clinical trials have suggested that EN in comparison to PN may maintain gut 
integrity, reduce intestinal permeability, and down regulate the systemic immune response 
syndrome (SIRS), thereby favorably affecting clinical outcome (Jabbar A et al, 2003). Further 
evidence suggests that not only is the route of feeding a factor in outcome, but specific 
agents in EN or PN (immune-modulating agents) such as probiotics or -3 fish oil may 
influence hospital length of stay (LOS) and rate of complications (Olah A et al, 2002; Lasztity 
N, 2005).  
2. Nutrition assessment in AP 
Severe AP is associated with high mortality. Adequate nutrition support improves clinical 
outcome. Nevertheless, several recent trials have focused primarily on the route of nutrition 
support and neglected the role of nutrition status assessment in tailoring nutrition support 
to individual needs (Lugli AK et al, 2007). 
Definition of an optimal nutritional regimen requires knowledge of energy requirements. 
Because pancreatitis is a serious disease, it is presumed to be associated with marked 
increases in energy expenditure. However, data for measured resting energy expenditure 
(REE) in patients with pancreatitis are limited. In a study aimed to assess the REE of patients 
with pancreatitis, Dickerson et al found a significantly higher value in those patients 
complicated by sepsis than those with pancreatitis alone. Septic patients had the largest 
percentage of hypermetabolic REE, >110% of predicted energy expenditure. They measured 
REE ranged from 77% to 139% of predicted energy expenditure according to Harris-
Benedict equation. The authors concluded that REE is variable in patients with pancreatitis; 
and the Harris-Benedict equation is an unreliable estimate of caloric expenditure. Septic 
complications are associated with hypermetabolism and may be the most important factor 
influencing REE (Dickerson R et al, 1991).   
AP increases the catabolism and proteolysis of skeletal muscle by as much as 80% in 
comparison with normal controls. Further, nitrogen losses have been shown to increase to as 
much as 20 to 40 g/d (Dickerson R, et al 1991). Decreased levels of total plasma proteins and 
rapid turnover proteins and marked decrease of the ratio of branched-chain to aromatic 
amino acid further characterize the hypermetabolic state (Havala T et al 1989; Shaw JHF, 
1986). Significant decrease in plasma essential aminoacids, with marked reductions of 
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almost all amino acids by skeletal muscle mass, have been reported clinically and 
experimentally (Bouffard YH et al. 1989). 
Another study reported the changes in body composition, plasma proteins, and REE during 
14 days of PN in patients with AP. Total body protein (TBP), total body water (TBW), and 
total body fat (TBF) were measured by neutron activation analysis and tritium dilution 
before and after PN. They studied 15 patients with AP, most of them with severe disease. 
The gains in body weight, TBW, TBP, Fat Free Mass, TBF and resting energy expenditure 
after 14 days were not significant. The authors concluded that body composition is 
preserved in AP during 14 days of PN. In patients without sepsis or recent surgery, PN was 
able to significantly increase body protein stores (Chandrasegaram MD et al, 2005). 
We have found that there are some nutritional parameters associated with mortality in AP. 
From the nutritional indicators measured, body fat reserves, renal function, muscle mass 
and immune function were the parameters that associated better with mortality in AP 
(Fuchs-Tarlovsky et al 1997). In another study aimed to validate these findings, we found 
that the group with higher mortality was associated with higher fat reserves, lower immune 
function or lymphocyte count and lower muscle reserves (Fuchs-Tarlovsky et al., 2010). 
3. Pancreatic rest and secretions 
Today, the validity of this concept of “pancreatic rest” is no longer accepted (Petrov MS et 
al, 2008; Ioannidis O et al, 2008; Talukdar R et al, 2009). Efforts to keep up with the increased 
energy demands in the case of AP are thwarted by the adage to put the pancreas at rest and 
the avoidance of pancreatic stimulation via gut luminal nutrition. The “pancreatic rest 
concept” assumes that the pancreatic rest promotes healing, decreases pain, and reduces 
secretion and leakage of the pancreatic juices in pancreas parenchyma and pancreas tissue 
(McClave SA et al, 1997). This concept disregards the presence of basal pancreatic exocrine 
secretion. Protein enzyme output is the responsible component for autodigestion of the 
gland and perpetuation of inflammatory process. Suppression of protein enzymes output 
alone with continued bicarbonate and fluid volume output may therefore be adequate in 
putting the pancreas to rest. 
3.1 Pancreatic secretion 
Pancreatic secretion and gut motility are tightly interwoven. Basal enzyme secretion is 20% 
of maximal enzyme secretion and it is regulated by cholinergic and cholecystokinin (CCK)-
mediated mechanisms. Feeding by mouth increases pancreatic secretion by involving 3 
stimulation levels: cephalic, gastric and intestinal level or phase (Spanier BM et al, 2011). The 
mere sight of food begins the process of pancreatic secretion and prepares the gut for 
digestion. Once the food enters the mouth and is chewed and swallowed there is a strong 
vagal stimulation which fortifies this response. The passage of food into the stomach 
produces mechanical effects, which further amplify the vagal response and, in addition, lead 
to gastric acid secretion. Finally, the movement of food and secretions through the pylorus 
into the duodenum culminates in the maximal stimulatory effect mediated by humoral CCK 
and secretin and also cholinergic excitation.  For many years it was considered that CCK 
was the chief stimulus for pancreatic enzyme secretion but now it is known that the 
response id complex and possibly mediated through cholinergic activation (O’Kaffe SJ et al, 
2006). 
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Further studies have demonstrated that as food progresses through the gastrointestinal (GI) 
tract, there are a series of feedback loops all the way down from the stomach to the colon. 
Passage of food into the jejunum also inhibits gastric emptying and intestinal transit. The 
presence of food in the ileum inhibits jejunal motility, presence of nutrients in the ileum 
inhibits not only pancreatic secretion but also gastric emptying and intestinal transit, and 
finally the transit of digested food into the colon augments the activation of the ileal brake 
(Van Citters GW, 1999). 
The duration of pancreatic enzyme response increases with greater caloric load. The 
pancreatic response is also influenced by the physical properties of the meal: mixed solid-
liquid meals induce a higher response than liquid or homogenized meals with similar 
energy content. In both instances, the rate of gastric emptying and thus duodenal delivery of 
nutrients are the key factors which determine the duration of the pancreatic secretion. The 
proportion of fat, carbohydrate, and protein contents within a meal also influence the 
duration and enzyme composition of the pancreatic response (Spanier BM et al, 2011). 
3.2 Pancreatic secretion with Enteral Nutrition (EN) 
The degree to which the pancreas is stimulated by EN is determined by the site in the GI 
tract at which feeding is infused. Feeding infused into the jejunum beyond the ligament of 
Treitz may bypass the cephalic, gastric, and intestinal phase of stimulation of pancreatic 
secretion, is less likely to stimulate CCK and secretin, and may stimulate inhibiting 
polypeptides (Abou S et al 2002, Russell MK at al, 2004, Scolapio JS et al, 1999). It has been 
demonstrated in human studies during jejunal feeding that the pancreatic enzyme output 
increased significantly over basal levels when it was delivered at the ligament of Treitz, 
whereas there was no significant increase during more distal jejunal feeding, 60 cm beyond 
the ligament of Treitz (Vu MK et al, 1999). 
Also, the composition of the infused feeds is important. There is some evidence to support 
an added benefit of elemental formulae for putting the pancreas to rest compared to 
standard formulae with intact protein or blenderized diets. Elemental diets cause less 
stimulation than standard formulas, because of their low fat content, the presence of free 
amino acids instead of intact proteins which bind to free trypsin in the gut, causing trypsin 
levels to fall, and less acid production from the stomach (Spanier MS et al, 2011). 
4. Nutrition therapy 
Nutrition therapy in the past has been governed by the principle that the gut should be put 
at rest with avoidance of any stimulation of pancreatic exocrine secretion. These concepts 
should now be replaced by the principle that pancreatic stimulation should be reduced to 
basal rates, but that the gut integrity should be maintained and that the stress response 
should be contained the likelihood of multiorgan failure (MOF), nosocomial infections, and 
mortality (McClave SA et al, 1998). 
Usually, the initial treatment of AP consists of a nil per os (NPO) regimen and 
administration of analgesics and ample intravenous fluids (Pandol SJ et al, 2007; Forsmark 
CE et al, 2007). However, within 24-48 hours EN should be initiated. The rationale for a 
period without food intake is the assumption that pancreatic stimulation by enteral feeding 
may aggravate pancreatic inflammation. Moreover, many patients are anorectic and may 
suffer increasing pain sensation when eating and ileus-related nausea and vomiting, and 
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delayed return of appetite (Banks PA et al, 2006; Forsmark CE et al, 2007; Meier R et al, 2005; 
Gianotti L et al, 2009). 
There have been studies regarding PN and PN supplemented with special nutrients. A 
Chinese study by Xian-Li et al evaluated the effects of supplemental parenteral glutamine. 
Forty one patients with severe AP were randomized to receive either PN or PN with 
glutamine. Use of PN with parenteral glutamine was associated with significantly less 
pancreatic infection (0.0% vs 23.8%, p<0.05) and fewer overall complications (20% vs 52%, 
p<0.05) compared to the use of PN alone without supplemental glutamine (Xian-Li H et al, 
2004). 
However today’s data trends more to the use of EN rather than PN as will be discussed 
below. 
4.1 Enteral vs Parenteral Nutrition 
Traditionally, patients with AP were either treated with strict rest or given PN to allow the 
pancreas to “rest” until the serum enzyme levels returned to normal. Unfortunately, some 
disadvantages are associated with the use of PN; one of the most serious is catheter related 
sepsis. Currently, EN is preferred for patients with AP because it is more cost effective than 
PN and results in fewer complications (Siow E, 2008). 
Despite fears that EN may exacerbate AP because of the stimulatory effect of luminal 
nutrients on trypsinogen synthesis, several randomized clinical trials have shown that 
outcome is better and the cost is lower if EN is used instead of PN (McClave SA et al, 1997; 
Abou-Assi S et al, 2002; Kalfarentzos F et al, 1997). EN can improve survival and reduce the 
complications accompanying severe AP. The explanations are: EN avoids PN related 
complications; luminal nutrition maintains intestinal health; enteral aminoacids are more 
effective in supporting splanchnic protein synthesis; EN may prevent the progression of 
MOF (Ionnidis O et al, 2008). 
In addition to its mucosal protective and immunomodulatory effects, EN is the most 
effective way of supporting intestinal metabolism. By down-regulating splachnic cytokine 
production and modulating the acute phase response, EN reduces catabolism and preserves 
protein (Winsdor AC et al, 1998). In addition, EN with a diet enriched with glutamine has 
beneficial effect on recovery of IgG and IgM-proteins with a trend to shorter disease 
duration (Grant J et al, 1984).  
There are some clinical studies that compared the use of PN versus EN in AP; the end points 
analyzed were mortality and complications. From 1996 to 2006 there were 5 studies which 
studied these outcomes; none of the studies yielded evidence of a difference in the mortality 
rates between patients given EN and patients given PN. Louie at al reported no deaths 
among patients given EN and 3 deaths among patients given PN. Those deaths however 
were attributed to complications of pancreatitis rather than to the mode of nutrition (Louie 
BE et al, 2005).  
Most of the randomized clinical studies reviewed reported higher complication rates among 
patients given PN than among the EN groups. Kalfatenzos at al reported significantly lower 
total number of complications for patients given EN compared with the PN group. 
Complications such as sepsis, nosocomial infection, catheter-related infection, and 
hyperglycemia are common findings in all studies, especially in patients who were given 
PN (Kalfarenzos FE et al, 1991). Abou-Assi et al showed a significant difference in rates of 
catheter–related infections between patients given EN and those with PN. The patients with 
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infections eventually required removal of the venous catheter and antibiotic treatment 
(Abou-Assi S et al, 2002). McClave at al. on the other hand, observed equal increases in the 
risk of infectious complications and the incidences of fluid and electrolyte imbalances 
(McClave SA et al, 1997).  
Louie at al found that the mean number of days of elevated blood glucose levels was 2.7 in 
the enteral group and 3.6 in the parenteral group (Louie BE, 2005). In all the above 
mentioned studies, the patients who received EN required fewer days to the start of oral 
diet than did the PN groups. Abou-Assi et al showed significant evidence that the patients 
given EN received 4.1 fewer days of nutritional support than the PN group. After disease 
resolution, 80% of the patients in EN progressed to oral diet without problem, compared 
with 63% in the PN group (Abou-Assi S et al, 2002).  
In addition, all of these clinical trials demonstrated that EN is cheaper than PN. Gupta et al 
provided significant evidence that patients given EN require a shorter length of 
hospitalization than patients given PN (Gupta R et al, 2003). 
In a recent systematic review about EN vs PN in pancreatitis the authors compared the 
effect of PN vs EN in patients with AP. The searches or randomized clinical trials were from 
2000 to 2008. Eight trials with a total of 348 participants were included. Comparing EN to 
PN in AP, the relative risk (RR) for deaths was 0.5 (95% CI 0.28 to 0.91), for MOF was 0.55 
(95% CI 0.37 to 0.81), for systemic infection was 0-39 (95% CI 0.23 to 0.65), for operative 
interventions was 0.44 (95% CI 0.29 to 0.67), for local septic complications was 0.74 (95% CI 
0.40 to 1.35), and for other local complications was 0.70 (95% CI 0.43 to 1.13). Mean LOS was 
reduced by 2.37 days in EN vs PN groups (95% CI - 7.18 to 2.44). Furthermore, a subgroup 
analysis for EN vs PN in patients with severe AP showed a RR for death of 0.18 (95% CI 0.06 
to 0.58) and RR for MOF of 0.46 (95% CI 0.16 to 1.29) (Al-Omran M et al, 2010). 
McClave et al concluded after performing a systematic review of literature comparing EN vs 
PN in AP that EN reduces oxidative stress, hastens resolution of the disease process, and 
costs less. Insufficient data exists to determine whether EN improves outcome over standard 
therapy. However, in those patients requiring surgery for complications of AP, meta-
analysis of 2 trials indicates that provision of EN postoperatively may reduce mortality 
(RR_0.26; 95% CI 0.0-1.09; p=0.06) compared with standard therapy (McClave SA et al, 
2006). 
In patients with AP, EN significantly reduced mortality, MOF, systemic infections, and the 
need for operative interventions compared with those who received PN. In addition, there 
was a trend towards a reduction in LOS. These data suggest that EN should be considered 
the standard of care for patients with AP requiring nutritional support. This 
recommendation is supported by the 2009 American Society for Parenteral and Enteral 
Nutrition (ASPEN) and Society for Critical Care Medicine (SCCM) Guidelines (McClave SA 
et al, 2009). Although hypertriglyceridemia may occasionally be the cause of AP, several 
years of clinical use has shown that PN containing lipid emulsions are safe in this condition 
(Leibowitz AB, 1992). Serum triglyceride levels should be monitored. Addition of heparin to 
PN infusate may decrease triglyceride levels in some patients (Benderly A et al, 1983). Table 
1 summarizes the available information on the special nutrients in enteral feedings. 
4.2 Nasojejunal (NJ) vs Nasogastric feeding (NG) 
NJ feeding tubes are placed blindly at the bedside, expecting spontaneous transpyloric 
migration or by using endoscopic or radiologic control.  
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Reference 
Author, year 
Study design  Type of 
nutrition 
Results 
 
Conclusion  
Abou –Assi  
et al, 2002 
Randomized  
controlled 
comparative 
clinical trial 
EN(NJ) 
 vs. PN 
Duration of feeding was shorter in the 
EN (6.7 vs. 10.8 days, p<0.05) and 
nutrition costs were lower in the EN 
group. Metabolic (p<0.003) and septic 
(p=0.01) complications were lower in 
the EN group. 
EN seems to be safer 
and less expensive 
than PN in AP. 
Kalfarentzos 
F et al, 1997 
Randomized  
controlled 
comparative 
clinical trial 
EN  
vs. PN 
Patients who received EN experienced 
fewer complications (P<0.05) , 
specially septic complications (P<0.01) 
than those receiving PN. PN costs 
were three times higher than EN. 
EN should be used 
preferentially in 
patients with severe 
AP. 
Winsdor AC  
et al, 1998 
Randomized  
controlled 
comparative 
clinical trial 
EN  
vs. PN 
The acute phase response and disease 
severity scores were significantly 
improved following EN (CRP: 156(117-
222) to 84(50-141), p<0.005; APACHE 
II scores 8(6-10) to 6(4- 8), P<0.0001) 
without change in the CT scan scores. 
In the PN group, these parameters did 
not change but there was an increment 
in the EndoCAb antibody levels and 
reduction in the CT scan scores.  EN 
did not show changes in the level 
EndoCAb level but there was an 
increase in the CT scan scores. 
EN moderates the 
acute phase response, 
and improves disease 
severity and clinical 
outcome despite 
unchanged pancreatic 
injury on CT scan.  
EN reduced systemic 
exposure to 
endotoxin and 
reduced oxidative 
stress; it also 
modulates the 
inflammatory and 
sepsis response in PA. 
Luie BE  
et al, 2005 
Randomized  
controlled 
comparative 
clinical trial 
PN vs. 
EN 
Reduction of CRP levels by 50% was 5
days faster with EN than with PN. 
Nutrition support costs were lower in 
the EN group. 
EN shows a trend 
toward faster 
attenuation of 
inflammation, with 
fewer septic 
complications and is 
the preferred therapy 
in terms of cost –
effectiveness. 
Gupta R 
et al, 2003 
Randomized  
controlled 
comparative 
clinical trial 
EN vs. 
PN 
Fatigue improved in groups but faster 
with EN. Oxidative stress was similar 
in both groups. 
There were no significant differences 
in complication rate and LOS was 
shorter in EN group (7(4-14)vs10(7-
26)days; p=0.05) 
The cost in the EN group was 
considerably less than PN. 
EN is safe in severe 
AP. It is as effective as 
PN and may be 
beneficial in the 
clinical course of 
disease. 
Abbreviations: AP= Acute Pancreatitis / EN = Enteral Nutrition / PN = Parenteral Nutrition / LOS = 
Length of Hospital Stay 
Table 1. Comparative studies between EN and PN 
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Eatock at al. performed a randomized controlled study on early NG versus NJ feeding in 
severe AP (Eatock FC et al , 2000;  Eatock FC et al, 2005). They found that NG feedings were 
very well tolerated and recommended that NG feedings should be considered a therapeutic 
option because of its simplicity, obviating the need for endoscopic or radiologic procedures. 
This study had several limitations, one of them being the failure to fluoroscopically confirm 
that the NJ tubes were appropriately positioned in the jejunum. There is no indication 
whether the NJ tubes were placed distal enough (at least 60 cms from the ligament of Treitz) 
to avoid gastric and pancreatic stimulation. The failure to find difference may have been 
related to continued gastric and duodenal stimulation occurring in both groups of patients. 
Similar findings from randomized studies were reported by Eckerwall et al who performed 
a randomized clinical trial to compare the efficacy and safety of early EN via NG tubes with 
PN. The authors reported that early NG EN in patients with severe AP was feasible, and 
resulted in better glucose control. No beneficial effects on the intestinal permeability or on 
the inflammatory response were seen by EN treatment (Eckerwall GE et al, 2006).  
Kumar et al performed a randomized clinical trial to compare early NJ with NG feeding in 
severe AP, and showed that that EN at a slow infusion is well tolerated by both NJ and NG 
routes in patients with severe AP. Neither feedings leads to recurrence or worsening of pain 
in patients with severe AP. They also reported that nutritional parameters remained 
unaffected because of inadequate caloric intake during the first week of feeding (Kumar A et 
al, 2006). 
Vu et al studied the activation of pancreatic secretion in 8 healthy volunteers in response to 
proximal or more distal jejunal delivery of nutrients into the small intestine. The authors 
concluded that continuous feeding into the distal jejunum does not stimulate exocrine 
pancreatic secretion (Vu MK et al, 1999). 
Piciucchi M et al assessed the rate of spontaneous tube migration and to compare the effects 
of naso-intestinal (NI) tube feeding in AP. They defined NI location as those tubes placed 
beyond the ligament of Treitz. The authors showed that spontaneous tube migration to an 
NI site occurred in 10 of 25 or 25% of the patients, while in 15 (60%) EN was started with an 
NG tube. EN through NG or NI were similar in terms of tolerability, safety, clinical goals, 
complications and hospital stay. As a conclusion, EN by NG tubes seem to provide a 
pragmatic alternative opportunity with similar outcomes in AP (Piciucchi M et al, 2010). 
McClave SA et al also commented in their meta-analysis that a wide range of tolerance to 
EN exists, irrespective of known influences such as mode (continuous versus bolus) and 
level of infusion within the GI tract (gastric versus postpyloric) (McClave SA et al, 2006).  
Patients with severe necrotizing pancreatitis may have gastric outlet obstruction or severe 
gastroparesis and many may have to be approached differently. Feeding into the stomach 
may be ineffective and possibly hazardous. Further multicenter randomized trials studies 
are needed to confirm whether NG feeding is a practical and effective form of management 
for patients with severe AP (Ioannidis O et al, 2008). Table 2 summarizes the available 
information on the special nutrients in enteral feedings. 
4.3 When to start nutrition support 
Per oral ingestion of nutrients is often hampered by abdominal pain with food aversion, 
nausea, vomiting, gastric atony, and paralytic ileus or by partial duodenal obstruction from 
pancreatic gland enlargement. The application of early EN may be limited by the severity of 
the pancreatitis attack and the occurrence of ileus (Spanier BWM, et al. 2011). 
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Reference  Study design  Via or 
Enteral 
Feeds  
Results Conclusion  
Eatock FC  
et al, 2005 
Randomized  
controlled 
comparative 
clinical trial 
 
NG vs. NJ Clinical differences 
between the two groups 
were not significant. 
Overall mortality was 
24.5% with five deaths in 
the NG group and seven 
in the NJ group. 
The simpler, cheaper, 
and easier to use NG 
feeding is as good as 
NJ feeding in  patients 
with objectively 
graded severe AP. 
Kumar A  
et al, 2006 
Randomized  
controlled 
comparative 
clinical trial 
NJ vs. NG Group1 (NG): Diarrhea 
occurred in 4 patients and 
there were 5 deaths, 1 
patient underwent 
surgery. 
Group 2(NJ): Diarrhea 
occurred in 3 patients, 
there were 4 deaths, and 2 
patients underwent 
surgery. 
EN at a slow infusion 
is well tolerated by 
both NJ and NG 
routes in patients with 
AP. Neither NJ nor 
NG feeding leads to 
recurrence or 
worsening of pain in 
AP. Nutritional 
parameters remained 
unaffected because of 
inadequate calorie 
intake during the first 
week of feeding. 
 
Piciucchi M  
et al, 2010 
Randomized  
controlled 
comparative 
clinical trial  
NG vs. NJ Spontaneous tube 
migration to NJ site 
occurred in 10/25(40%) 
prospectively enrolled 
severe AP patients; while 
in 15 (60%) nutrition was 
started with a NG tube. 
CT severity index was 
higher in NG tube patients 
than in NI (mean 6.2 vs. 
4.7, P = 0.04).  
Spontaneous distal 
tube migration is 
successful in 40% of 
severe AP patients, 
with higher CT 
severity index 
predicting IG 
retention; in such cases 
EN by NG tubes 
seems to provide a 
pragmatic alternative 
opportunity with 
similar outcomes. 
Abbreviations: AP= Acute Pancreatitis / NJ = Nasojejunal feeding / NG = Nasogastric feeding /IG = 
Intragastric/NI=Nasointestinal 
Table 2. Comparative studies between NJ and NG 
The precise timing for initiating enteral support has not been specifically addressed in the 
pancreatitis population but has been studied to a large extent in the critically ill population. 
EN has been described as a rational and acceptable option of supporting critically ill patients 
after major abdominal surgery, as well as in patients with AP (Windsor AC et al, 1998). 
Early EN starting prior to 48 hours from admission in critically ill patients is associated with 
a significant 24% reduction in infectious complications and 32% reduction in mortality 
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compared with delay feedings started after that point time (McClave SA et al, 2009; Heyland 
DK et al, 2003) 
Olah et al demonstrated that early jejunal feeding with an elemental diet within 48 hours 
after the onset of symptoms when possible, and was more useful and cheaper than PN. They 
concluded that early jejunal feeding reduced septic complications in necrotizing AP in 
combination with adequate antibiotic prophylaxis (Olah A et al, 2002). 
Pupelis G et al performed a randomized clinical trial measuring the feasibility and 
effectiveness of jejunal feeding after surgery due to peritonitis in severe AP. They concluded 
that early jejunal feeding resulted in 3.3% mortality as opposed to 23.3% in the control group 
(p=0.05) and that jejunal feeding is feasible and effective in postoperative treatment of 
patients due to secondary peritonitis because of AP (Pupelis G et al, 2001). Table 3 
summarizes the available information on the special nutrients in enteral feedings. 
 
Author, reference, 
year  
Study design  Time to start 
nutrition 
therapy  
Results Conclusion  
Pupelis G et al, 2001 Randomized  
controlled 
comparative 
clinical trial 
Patients in EN 
group received 
the daily mean 
of 1294.6 (362.6) 
kcal including 
830.6 (372.7) 
kcal enterally, 
versus 472.8 
(155.8) kcal 
daily in the 
control group (P 
< 0.0001). 
 
The first surgical 
intervention resulted in 
3.3% of re-laparotomies 
in EN patients, caused by 
unresolved peritonitis, 
versus 26.7% in the 
control subjects (P = 0.03). 
Recovery of bowel transit 
took significantly less 
time in the EN patients 
(mean: 54.6 h versus 76.8 
h in control subjects, P = 
0.01). EN resulted in 3.3% 
mortality as opposed to 
23.3% in the control 
group (P = 0.05). 
EN is feasible and 
effective in 
postoperative 
treatment of 
patients due to 
secondary 
peritonitis or severe 
pancreatitis. 
Improved bowel 
and peritoneal 
function could be 
the main impact of 
EN. 
 
Oláh et al, 2002 Randomized  
controlled 
comparative 
clinical trial 
1st phase: PN 
was compared 
with early 
(within 24-72 h 
after the onset 
symptoms) EN. 
Septic complications were 
lower in the EN group (P 
= 0.08, chi(2) test) 
The combination of 
early EN and 
selective, adequate 
antibiotic 
prophylaxis may 
prevent multiple 
organ failure in 
patients with AP. 
 
Kalfarentzos, 1991 Randomized  
controlled 
comparative 
clinical trial 
Group1:EN in 
the  first 72 
hours an EN 
later in the 
course of the 
disease  
Group 1: 23% 
complications and 13% 
mortality 
Group 2: 95.6% 
complications rate and 
38% mortality 
P<0.01 
Early EN reduced 
complications rate 
and mortality in AP 
Abbreviations: Se=Selenium / AP= Acute Pancreatitis / EN = Enteral Nutrition 
Table 3. Comparative studies between early and late EN 
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4.4 Types of enteral formula recommended 
A few studies to date compare the results of feeding elemental, semielemental, and 
polymeric diets to patients with AP (Marik PE, 2009 and Talukdar R et al, 2009). Elemental 
formulas are completely predigested and consist of aminoacids, simple sugars, and enough 
fat to prevent essential fatty acid deficiency. Semielemental formulas required less digestion 
than polymeric foods and contain peptides of varying chain length, simple sugars, glucose 
polymer, or starch and fat primarily as medium chain triglycerides. Polymeric feeds contain 
non-hydrolyzed proteins, complex carbohydrates, and longchain triglycerides. Based on the 
assumption that elemental and semielemental formulas cause less pancreatic stimulation 
than standard formulas, most EN studies have used an elemental or semielemental formula. 
Although there is a variety of data on the use of standard enteral formula in such patients 
(Spanier BWM et al, 2011), both Windsor et al and Pupelis et al have shown that polymeric 
formula can be safely fed through jejunal tubes in AP patients (Windsor ACJ, 1998;  Pupelis 
G et al., 2001). 
A few studies have defined the benefits of semielemental versus polymeric formulas in 
severe AP. Cravo et al found a similar tolerance in 102 patients with AP given 
semielemental versus polymeric formulas (Cravo M et al, 1989). In a randomized trial using 
semielemental and polymeric formulas in 30 AP patients, Tiegou et al showed that both 
formulas were well tolerated and well absorbed, but the semielemental group had less 
weight loss and shorter LOS compared with the polymeric group (Tiegou IE, 2006). Petrov 
et al performed an adjusted meta-analysis using 20 randomized controlled trials, including 
1070 patients. None of the studies was associated with a significant difference in feeding 
tolerance when comparing the tolerance and safety of EN formulations in patients with AP. 
The use of a semielemental diet versus polymeric formulation did not show significant 
differences (RR= 0.62). The authors concluded that the use of polymeric compared with 
semielemental formulation, does not lead to a significant higher risk of feeding intolerance, 
infectious complications, or death in AP patients (Petrov MS et al, 2008; Petrov MS et al, 
2009). Table 4 summarizes the available information on the special nutrients in enteral 
feedings. 
It should be remembered that semielemental or elemental diets are sevenfold as expensive 
as polymeric feeds, and in some countries perhaps even more expensive. In summary, the 
evidence base to use just semielemental or elemental formulas becomes less clear (Spanier 
BWM et al, 2011). 
4.5 Use of supplements or special nutrients in Enteral Nutrition 
The routine use of glutamine, immunonutrition, prebiotics and probiotics in AP is not 
supported by large scale clinical studies. Two studies evaluated immune-enhancing 
formulas that contain glutamine, arginine and fibers or glutamine, arginine and -3 fatty 
acids, vitamins, and micronutrients (Hallay J et al, 2001; Pearce CB et al, 2006). Hallay et al 
compared a standard formula with a glutamine-enriched formula on immunologic 
parameters in 16 patients with AP; they found that the recovery of the immunological 
parameters was better and the time of disease recovery was shorter in the glutamine treated 
group. Other authors also reported the beneficial effect of a glutamine-rich multifiber diet as 
compared to a standard fiber diet; the trend of IgG and IgM, as well as visceral proteins 
(prealbumin and Retinol Binding Protein) with shorter disease duration was seen in the 
treatment group (Hallay J et al, 2001).  
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Author, 
reference, 
year  
Study design  Types of formula  Results Conclusion  
Tiegou 
IE, 2006 
Randomized 
comparative 
prospective 
controlled 
clinical trial 
Semi-elemental vs 
polymeric formula. 
 
Tolerance was good in 
both groups (semi-
elemental vs. polymeric: 
VAS, 7.4 +/- 0.6 vs. 7.1 +/- 
0.6 NS; number of stools 
per 24 hours, 1.7 +/- 0.4 vs. 
1.8 +/- 0.4, NS). 
Steatorrhea was lower 
than normal in both 
groups. In the semi-
elemental formula group, 
the hospital LOS was 
shorter (23 +/- 2 vs. 27 +/- 
1, p = .006) and weight loss 
was less marked (1 +/- 1 
vs. 2 +/- 0, p = .01). One 
patient in semi-elemental 
group and 3 patients in 
polymeric group 
developed an infection 
(NS). 
Semi-elemental and 
polymeric nutrition 
are very well 
tolerated in 
patients with AP. 
Nutrition with a 
semi-elemental 
formula supports 
the hypothesis of a 
more favorable 
clinical course than 
nutrition with a 
polymeric formula. 
 
Windsor 
ACJ, 1998 
Randomized  
Clinical trial 
 
Polymeric  formula 
‘’Osmolite’’®,‘’Fresubin’’® 
Following seven days of 
enteral nutritional support 
there was a significant 
reduction in serum CRP 
from 156 (117–222) mg/l to 
84 (50–141) mg/l (p<0.005) 
and APACHE II scores fell 
from 8 (6–10) to 6 (4–8) 
(p<0.0001) in the enterally 
fed group. 
Polymeric formula 
can be safely fed 
through NJ tubes in 
AP patients.              
Enteral feeding in 
acute pancreatitis is 
practical. 
Furthermore is 
both feasible and 
desirable in the 
management of 
patients with acute 
pancreatitis. 
Cravo M 
et al, 1989 
Prospective  Elemental (group 1/  n=47) 
vs  polymeric formula 
(group 2 / n=44) 
 
Mean nutrient intake was 
higher in group II 
(p<0.001): Kcal: 1447+228 
vs 
1161+182; protein: 45+9 vs 
30+8g; fat: 31+10 vs 4+3g. 
Local complications rate 
was similar (17% in group 
I vs 7% in group II) and 
LOS was: In group I -6.6±3 
.2 vs Group II-6.3±2.2d. 
Elemental diets 
offer no advantage 
upon polymeric 
balanced diets. 
 
Abbreviations: NS=Non significant / AP= Acute Pancreatitis / EN=Enteral Nutrition 
/NJ=Nasojejunal/ LOS=Length of hospital stay 
Table 4. Comparative studies between the efficacies of the different types of EN  
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Pearce at al supplemented arginine, glutamine, -3 fatty acids and antioxidants in 31 
patients with severe AP in a randomized control trial; their findings suggest that an increase 
in C-Reactive Protein was found in the supplemented group compared with the control 
group. No significant differences were found in the length of hospital stay. Although a 
lower incidence of pneumonia and MOF, and shorter length of ICU and hospital stay was 
observed in the immunonutrition group, none of these differences reached statistical 
significance (Pearce CB et al, 2006). 
De Beaux et al randomized 14 patients with severe AP to receive standard PN of isocaloric, 
isonitrogenous, glutamine-enriched PN; only 13 patients completed the study. There was a 
trend for the glutamine supplemented group to show improved lymphocyte proliferation, 
increased T-cell DNA synthesis and decrease release of the pro-inflammatory cytokine IL-8 
(De Beaux AC et al, 1998). 
A double blind randomized clinical trial by Olah et al evaluated the effects of probiotics 
added to EN. They proposed that the rapid disappearance of commensal flora in AP, 
combined with overgrowth of potentially pathogenic organisms, provided the rationale for 
probiotic therapy. The authors divided patients into 2 groups; the treatment group, who 
received a preparation containing Lactobacillus plantarum together with a substrate of oat 
fiber for one week by NJ tube; and the control group who received heat inactivated 
Lactobacillus strain preparation. Infected pancreatic necrosis and abscesses occurred in 4% of 
the patients in the treatment group as compared to 30% in the control group (p=0.023). The 
mean hospital LOS was shorter in the treatment group as well (p<0.05) (Olah A et al, 2002). 
Lasztity evaluated whether provision of -3 polyunsaturated fatty acids (-3 PUFA) or fish 
oil could alter the course of disease in AP through modulation of eicosanoid synthesis. 
Supplementation of EN with 3.3 g/d of -3 PUFA for 7 days in the treatment group resulted 
in a significant decrease in hospital LOS (p<0.05) and duration of nutrition therapy (Lasztity 
N, 2005). 
 
Author, 
reference, year  
Study design  Special nutrient 
in formula 
Results Conclusion  
Hallay J  
et al, 2001 
Randomized 
clinical trial 
 
“Stresson “ ® 
Multi Fibre  vs 
“Nutrison” ® 
Fibre 
The treatment with 
glutamine-rich “Stresson“ 
® resulted in significant 
elevations in the serum 
levels of IgG, retinol 
binding protein, compared 
to the effects of Nutrison 
Fibre. In addition, the 
recovery of treated patients 
was significantly shorter in 
the “Stresson” ® Multi 
Fibre group than in the 
“Nutrison “ ® Fibre group. 
The “Stresson” ®  
Multi Fibre nutrient 
treatment of patients 
treated for AP seems 
to have clinical 
benefit based upon 
the fast recovery of 
IgG, IgM proteins 
and the 
immunological 
defense 
mechanisms. 
Pearce CB  
et al, 2006 
Double-blind 
Randomized 
controlled 
trial 
Glutamine, 
arginine, 
tributyrin and 
antioxidants vs  an 
isocaloric 
isonitrogenous 
After 3 days of feeding, in 
the study group 2/15 (13%) 
of patients had reduced 
their CRP by 40 mg/L or 
more. In the control group 
6/16 (38%) of patients had 
reduced their CRP by this 
The cause of the 
unexpectedly higher 
CRP values in the 
study group is 
unclear. 
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Author, 
reference, year  
Study design  Special nutrient 
in formula 
Results Conclusion  
amount. This difference 
was found to be near the 
statistical significant limit 
(P=0.220). 
Oláh A  
et al, 2002 
Randomized 
clinical trial 
 
Group 1: Received 
Lactobacillus 
plantarum 
together with a 
substrate of oat 
fibre. 
Group 2(control): 
Received a 
isonitrogenous 
formula but the 
Lactobacillus was 
inactivated by 
heat. 
Infected pancreatic necrosis 
and abscesses occurred in 1 
of 22 patients in the 
treatment group, compared 
with 7 of 23 in the control 
group (P = 0.023). The 
mean length of stay was 
13.7 days in the treatment 
group versus 21.4 days in 
the control group (p=NS). 
Supplementary L. 
plantarum was 
effective in reducing 
pancreatic sepsis 
and the number of 
surgical 
interventions. 
Lasztity, 2005 Randomized 
clinical trial  
N-3 PUFAs (fish 
oil) enterally 
(3.3g/day for 5-7 
days). 
The n-3 to n-6 LCPUFA 
ratios increased 
significantly in serum lipids 
of the patients receiving 
supplementation. 
 The SOD activity was 
significantly higher at day 3 
in the supplemented group 
(P<0.05). 
The use of enteral 
formula enriched 
with n-3 PUFAs in 
the treatment of AP 
seems to have 
clinical benefits 
based upon the 
shortened time of 
jejunal feeding and 
hospital stay 
Kuklinski B  
et al, 1995 
Randomized 
clinical trial 
Antioxidant 
treatment sodium 
selenite as a water 
soluble redox 
substance 
represented an 
alternative 
With a well-timed selenium 
therapy the rates of 
lethality complications and 
operation dropped 
drastically. Complications 
occurred if the therapy 
began too late (if patients 
were administered too late) 
and in biliary forms. 
An improvement in 
the prognosis of 
acute pancreatitis 
can be achieved if 
antioxidant 
selenium therapy 
with sodium Se is 
introduced in time. 
In rare cases total 
necroses and 
complications in 
organs only 
occurred in those 
patients who were 
admitted to this 
therapy too late. 
Abbreviations: Se=Selenium / AP= Acute Pancreatitis / PUFA = Polyunsaturated fatty acids / SOD= 
Superoxide dismutase 
Table 5. Special Nutrients in Enteral Feeding  
In a study by Kuklinski et al. reduction of plasma selenium levels was noted in patients with 
AP; positive results after the addition of selenium into the intestinal diet of these patients 
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was reported (Kuklinski B et al, 1995). Despite the limited number of reports on this subject, 
the European Society of Parenteral and Enteral Nutrition (ESPEN) Guidelines recommend 
the use of PN with selenium in patients with AP (Meier R et al, 2006). 
In summary, the beneficial effect of EN on patient outcome in AP may be enhanced by 
providing certain supplements. Although adding arginine, glutamine, -3 fatty acids, or 
specific probiotic preparation to the EN in patients with AP may result in reduction of 
hospital LOS, duration of nutrition therapy, or certain complications (when compared with 
the use of EN alone without the supplements), not enough information is available to make 
firm and specific recommendations. The addition of parenteral glutamine to PN should be 
considered in order to shorten hospital LOS and duration of nutrition therapy (when 
compared with PN alone without the supplement (McClave SA et al, 2006). Table 5 
summarizes the available information on the special nutrients in enteral feedings. 
5. Conclusions 
Most patients with AP have mild disease and do not need additional nutrition support 
during admission. According to guidelines, nutritional support is generally indicated if 
patients cannot consume normal food after 5-7 days when it becomes evident that the 
patients will not be able to tolerate oral intake for prolonged period of time (7 days or more) 
(Spanier BM et al, 2011). However, in a malnourished patient, especially if critically ill, 
nutrition therapy in some form must be provided earlier, to avoid caloric deficits. 
Nutrition therapy by enteral route is now the modality of choice for patients with severe AP. 
Recent guidelines have summarized the levels 1 and 2 evidence in support of the preferred 
role of EN according to safety, cost, and ease of administration. Patients with AP should be 
provided EN early because such therapy modulates the stress response, promotes more 
rapid resolution of the disease process, and results in better outcome. EN has beneficial 
influence on the disease course and should be initiated as early as possible (within 48 hours 
of admission). Large multicenter studies are still needed to confirm the safety and 
effectiveness of NG feeding when compared with NJ feeding and to investigate the role of 
early (within 48 hours) versus late nutrition support. When distal jejunal access is not 
possible to attain or maintain, intragastric feeding can be cautiously initiated, following safe 
practice standards. The clinical evidence to use semielemental diets is still weak. Routine use 
of supplementation formulas with glutamine and probiotics or immune-enhancing diets in 
AP cannot be recommended at this time.  
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Acute Pancreatitis (AP) in approximately 80% of cases, occurs as a secondary complication related to
gallstone disease and alcohol misuse. However there are several other different causes that produce it such
as metabolism, genetics, autoimmunity, post-ERCP, and trauma for example... This disease is commonly
associated with the sudden onset of upper abdominal pain that is usually severe enough to warrant the patient
seeking urgent medical attention. Overall, 10-25% of AP episodes are classified as severe. This leads to an
associated mortality rate of 7-30% that has not changed in recent years. Treatment is conservative and
generally performed by experienced teams often in ICUs. Although most cases of acute pancreatitis are
uncomplicated and resolve spontaneously, the presence of complications has a significant prognostic
importance. Necrosis, hemorrhage, and infection convey up to 25%, 50%, and 80% mortality, respectively.
Other complications such as pseudocyst formation, pseudo-aneurysm formation, or venous thrombosis,
increase morbidity and mortality to a lesser degree. The presence of pancreatic infection must be avoided.
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